YOKNEAM, Israel, September 19, 2017 /PRNewswire/ --
- The post marketing registry will assess the real-life safety and performance of the TIGERTRIEVER revascularization device
Today, Rapid Medical, a company focused on the development of neurovascular interventional devices, announced that the first patient was enrolled to the TIGERTRIEVR registry at the Cantonal Hospital of Lucerne, Switzerland. The TIGERTRIEVER is a one-of-a-kind, fully-visible, controllable stentriever that is adjusted to perfectly fit the dimensions of a blocked blood vessel causing acute ischemic stroke. The TIGERTRIEVER registry is a European multi-center registry that will enroll patients from leading centers in France and Switzerland. It is the first registry that is designed to demonstrate the benefits of the TIGERTRIEVER in real-life usage.
Dr. Alexander von Hessling, Division of Neuroradiology, Cantonal Hospital of Lucerne, Switzerland described the first procedure in the registry: "An 87 years old male was admitted to the hospital with an acute stroke, suffering from severe aphasia and right sided hemiplegia. The patient was treated with the TIGERTRIEVER which removed a large clot from his left internal carotid artery in a single attempt. The procedure went very well and took 19 minutes, including placement of a carotid stent due to a severe carotid stenosis. The patient recovered quickly and completely and was even able to sign his consent, to be enrolled in this registry study, one hour after finishing the procedure. This is a very exciting and promising device: It is controllable and fully visible. We are happy to have enrolled the first patient and to have a leadership role in this registry".
In addition to the post marketing registry, Rapid Medical plans to initiate a prospective multi-center clinical study for FDA clearance for the Tigertriever. The TIGER study is planned to start enrolling patients in leading centers in US, Europe and Israel during the first half of 2018.
About Rapid Medical
Rapid Medical is developing game-changing devices for endovascular treatments. Rapid Medical is the maker of TIGERTRIEVER, the first-ever controllable, fully visible stentriever that is designed to treat ischemic stroke patients. And the COMANECI, the first-ever controllable aneurysm neck-bridging device. TIGERTRIEVER and COMANECI are CE marked for use in Europe. Rapid Medical has recently announced closing of a $9M financing round to advance commercialization of its products. More information is available at http://www.rapid-medical.com
SOURCE Rapid Medical